Breast Cancer

Patients with primary breast cancer receiving neoadjuvant letrozole will undergo radiological assessment with digital mammogram, ultrasound (US) including shearwave elastography (SWE). These will be performed at 3 monthly intervals until surgical intervention is considered feasible.

Shearwave elastography

Patients will be receiving neoadjuvant letrozole as standard therapy for breast cancer

Letrozole

Core biopsies will be taken at diagnosis, and at the time of surgery to allow biological assessment of changes in tumour

Breast core biopsy

Breast MRI scans will be performed at time of diagnosis and prior to surgery to allow comparison of MRI change and response to treatment

Magnetic Resonance Imaging

Stefani Clinical Trials Unit, Ninewells Hospital and Medical School

Radiological and Biological Tumoural and Peri-tumoural Factors in Neoadjuvant Endocrine-treated Breast Cancers

Pathological response to treatment by proliferation (Ki67) (%)

MRI - digital contrast enhanced (DCE) and diffusion weighted imaging (DWI)

peri-tumoural immunohistochemical analysis

Jane MacAskill

Dr. Jane MacAskill

NHS Tayside

A percutaneous (utlrasound-guided) radiofrequency ablation (RFA) of the tumor will be performed by the radiologist under general anesthesia. Immediately after, excision of the tumor with appropriate margin will be accomplished.

Normal excision of the tumor according to the protocol

After tumor ablation and excision of the tumor, the pathologist performed a macroscopic study of the specimen,measuring the distance between the tumor and the margin in order to indicate if extensions are mandatory. Secondly and delayed, margins will be evaluated microscopically by H&E stain. Furthermore, the tumoral viability in the ablation zone will be evaluated by NADH-diaphorase, COX and tunnel.

Radiofrequency ablation

Hospital Universitario Bellvitge

Radiofrequency Ablation in Breast Cancer

Impact of Radiofrequency Ablation on Surgical Margins in Early Stage of Malignant Breast Tumors

The pathologist performed a macroscopic study of the specimen, measuring the distance between the tumor and the margin in order to indicate if extensions are mandatory.

Adverse effects and cosmetic result will be evaluated 15 days after the procedure

Tumoral viability in the ablation zone will be evaluated by NADH-diaphorase, COX and tunel

Amparo Garcia-Tejedor

MD PhD

Hospital Universitari de Bellvitge

Women diagnosed with breast cancer by a positive biopsy test after mammography.

Women with negative biopsy result done due to a suspicious mammography exam.

Men and women diagnosed with colon cancer by a positive colonoscopy and biopsy.

Men and women with negative colonoscopy and biopsy tested due to complaints indicating the possibility of colon cancer.

Colon Cancer

RAMBAM medical center

Carmel medical center

Breath Testing for Breast and Colon Cancer Diagnosis- NaNose Study

Observational Study Aimed to Characterize a System for Breast and Colon Cancer Diagnosis by Breath Testing - NaNose Study

Sensitivity and specificity of NaNose system in diagnosing cancer

NaNose LTD

Rambam Health Care Campus

Technion, Israel Institute of Technology

SOD1 inhibitor ATN-224

exemestane

protein expression analysis

proteomic profiling

laboratory biomarker analysis

pharmacological study

Cancer Research UK Medical Oncology Unit at Churchill Hospital & Weatherall Institute of Molecular Medicine - Oxford

Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer

A Cancer Research UK Randomised Phase II Trial of ATN-224 (Copper Binding Agent) in Combination With Exemestane Versus Exemestane Alone in Post-menopausal Women With Recurrent or Advanced, Oestrogen and/or Progesterone Receptor Positive Breast Cancer

oxidase/cancer mamar

Radiological and Biological Tumoural and Peri-tumoural Factors in Neoadjuvant Endocrine-treated Breast Cancers

Radiofrequency Ablation in Breast Cancer

Breath Testing for Breast and Colon Cancer Diagnosis- NaNose Study

Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer

Cea mai completă bază de date cu plante medicinale susținută de știință